The partial clinical hold raises new development risk for the $795 million epilepsy partnership, although dosing continues and the fully enrolled RISE3 trial remains on schedule.
Key Takeaways
- The FDA paused new enrollment in Biohaven’s opakalim program because available data were insufficient to assess the human risk of a metabolite observed in rodent studies.
- More than 600 randomized participants may continue treatment, and the fully enrolled RISE3 trial remains on track for a topline readout in the second half of 2026.
- The hold affects an epilepsy asset that SK Biopharmaceuticals agreed to license globally in a transaction valued at up to $795 million.
Data Snapshot
| Item | Details |
|---|---|
| Candidate | Opakalim |
| Development code | BHV-7000 |
| Originator | Biohaven |
| Planned global licensee | SK Biopharmaceuticals |
| Mechanism | Selective Kv7.2/7.3 potassium channel activator |
| Lead indication | Refractory focal epilepsy |
| Development stage | Phase 2/3 |
| FDA action | Partial clinical hold |
| Hold issued | September 4, 2026 |
| Immediate restriction | New patient enrollment paused |
| Existing participants | Dosing continues |
| RISE3 / BHV7000-303 | Fully enrolled; topline results expected in H2 2026 |
| RISE2 / BHV7000-302 | Dosing continues; new enrollment paused |
| Near-term cash consideration | $400 million |
| Total disclosed deal value | Up to $795 million, plus royalties |
The hold delays recruitment rather than stopping the entire program. Its eventual impact will depend on whether the metabolite finding is relevant to humans and how quickly Biohaven can resolve the FDA’s questions.
What Happened
The US Food and Drug Administration (FDA) placed Biohaven’s opakalim (BHV-7000) program under a partial clinical hold after reviewing nonclinical findings involving a specific drug metabolite observed in rodents.
The agency concluded that the available information was insufficient to assess the metabolite’s potential risk to human participants. It therefore paused new enrollment pending additional nonclinical data.
The restriction does not apply to patients already randomized. More than 600 participants may continue treatment across the program, including its open-label extension study. Biohaven has voluntarily applied the same enrollment pause at sites outside the United States.
The two pivotal trials are affected differently. RISE3, formally BHV7000-303, completed enrollment in June and remains on schedule to report topline results in the second half of 2026. RISE2, or BHV7000-302, can continue dosing existing participants but cannot recruit new patients while the hold remains in place.
Biohaven expects additional nonclinical data within weeks. The company emphasized that the finding may be specific to rodents and may not represent a human safety risk. Opakalim has been administered to more than 1,200 participants and has generally been described as well tolerated to date. (Biohaven SEC filing)
Why It Matters
A partial clinical hold is narrower than a complete shutdown, but it introduces uncertainty at a sensitive point in opakalim’s development.
Opakalim is a once-daily oral drug designed to activate Kv7.2/7.3 potassium channels. These channels help stabilize neuronal electrical activity, making excessive repetitive firing—and therefore seizures—less likely. Biohaven is developing the drug as adjunctive treatment for refractory focal epilepsy.
The program’s value proposition rests on combining seizure control with limited central nervous system adverse effects. Biohaven has specifically highlighted low rates of somnolence, dizziness and fatigue, attributes that could distinguish opakalim from other antiseizure medicines.
The new concern is not evidence that opakalim has caused toxicity in patients. It is an unresolved toxicology question concerning a metabolite produced as the drug is broken down.
That distinction matters. If subsequent testing shows that the metabolite is rodent-specific or that human exposure remains well below a relevant threshold, the FDA could lift the hold without materially changing the program. A finding that requires additional monitoring, dose changes or longer toxicology studies would create a more substantial delay.
Fierce Biotech reported that the hold prevents new recruitment while allowing already enrolled patients to remain on treatment. The publication also noted that the timing places pressure on a recently announced licensing transaction involving the program. (Fierce Biotech coverage)
The Hold Arrived Nine Days After the SK Deal
Biohaven and SK Biopharmaceuticals announced their global licensing agreement on August 26, nine days before the FDA issued the partial hold.
Under the agreement, SK Biopharmaceuticals will obtain an exclusive worldwide license to opakalim and the broader Kv7 platform once the transaction closes. Biohaven is due to receive $350 million at closing and another $50 million in 2027, providing $400 million in near-term cash.
Biohaven is also eligible for $150 million in development and regulatory milestones. SK will assume up to $245 million in specified obligations associated with Knopp Biosciences and future Kv7 programs. Together, these components bring the disclosed transaction value to as much as $795 million, excluding sales royalties.
The total represents approximately 1.1 trillion won, while the near-term cash consideration equals approximately 556 billion won, based on an illustrative exchange rate of $1 to 1,390 won.
Biohaven stated that it had disclosed all clinical and nonclinical data—including information related to the metabolite characterization—to SK Biopharmaceuticals before the agreement was signed. The companies are continuing the regulatory process required to close the transaction. (Biohaven–SK Biopharmaceuticals agreement)
This disclosure suggests that SK was aware of the underlying nonclinical issue, although it does not establish how either company assessed the probability or potential consequences of an FDA hold.
RISE3 Now Carries More Weight
The immediate value of the opakalim program increasingly depends on RISE3.
Both pivotal studies are randomized, double-blind and placebo-controlled trials evaluating changes in 28-day average seizure frequency among adults with refractory focal epilepsy. RISE3 is testing 50 mg and 75 mg doses, while RISE2 still requires additional enrollment.
A positive RISE3 result would preserve the clinical rationale for opakalim, but it would not resolve the metabolite question. Efficacy and nonclinical toxicology remain separate regulatory requirements.
The program must therefore clear two independent hurdles:
- RISE3 must demonstrate meaningful seizure reduction with acceptable tolerability.
- Biohaven and SK must show that the rodent metabolite does not create an unacceptable risk for human participants.
If the toxicology issue is resolved quickly, the main consequence may be a limited delay to RISE2. A prolonged hold could postpone completion of the second pivotal trial and any subsequent New Drug Application (NDA).
The Competitive Window May Shift Toward Xenon
The enrollment pause may give Xenon Pharmaceuticals additional room to advance azetukalner, another late-stage Kv7 potassium channel modulator for focal-onset seizures.
Opakalim and azetukalner are not identical products, and no head-to-head evidence is available. Their eventual positions will depend on seizure reduction, tolerability, dosing convenience and the timing of regulatory submissions.
Before the hold, opakalim’s proposed once-daily administration without titration supported a potentially attractive commercial profile. That advantage becomes less meaningful if its regulatory timeline falls behind.
Azetukalner may therefore benefit from a wider first-mover window even if opakalim’s human safety profile remains unchanged. The scale of that advantage will depend on the duration of the FDA review rather than the existence of the hold alone.
BP View
The partial clinical hold is a material setback, but the available evidence does not support treating it as a clinical safety failure.
The FDA has identified an information gap. Biohaven must now determine whether a metabolite detected in rodents is produced at relevant levels in humans and whether it poses a meaningful risk. The answer could range from a species-specific finding with limited consequences to a problem requiring additional studies or development changes.
For SK Biopharmaceuticals, the more important issue is not whether the metabolite information existed before signing; Biohaven says it was disclosed. The real test is whether the deal’s due diligence and contractual structure adequately accounted for the possibility of regulatory intervention.
RISE3 remains the near-term pivot. Strong efficacy data and a rapid lifting of the hold would preserve the strategic logic of adding opakalim to the Xcopri franchise. Weak clinical results or a prolonged toxicology review would place both the asset and the economics of the transaction under greater pressure.
The SK deal remains intact, but opakalim has shifted from a straightforward portfolio-expansion story to an early test of SK Biopharmaceuticals’ development and regulatory execution.

Related Post
Another epilepsy transaction shows how drugmakers are expanding their neurology portfolios through differentiated approaches to seizure control.
Read my previous analysis of Jazz Pharmaceuticals’ $1.32 billion investment in a precision therapy for rare epilepsy.
Jazz Bets $1.32 Billion on a Precision Therapy for Rare Epilepsy
About BP
Biopharma Perspective provides independent analysis of pharmaceutical and biotechnology news, connecting clinical data, regulatory decisions and competitive strategy.
Have a question about my analysis or another angle you would like to discuss? Leave a comment—I’d be happy to hear your thoughts.


Leave a Reply